- Home
- OABI vs CDXS Comparison
OABI vs CDXS Comparison
Compare OABI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- CDXS
- Stock Information
- Founded
- OABI 2012
- CDXS 2002
- Country
- OABI United States
- CDXS United States
- Employees
- OABI N/A
- CDXS N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- OABI Health Care
- CDXS Industrials
- Exchange
- OABI Nasdaq
- CDXS Nasdaq
- Market Cap
- OABI 388.5M
- CDXS 406.9M
- IPO Year
- OABI N/A
- CDXS 2010
- Fundamental
- Price
- OABI $3.22
- CDXS $5.13
- Analyst Decision
- OABI Strong Buy
- CDXS Buy
- Analyst Count
- OABI 4
- CDXS 2
- Target Price
- OABI $9.00
- CDXS $11.00
- AVG Volume (30 Days)
- OABI 448.8K
- CDXS 739.7K
- Earning Date
- OABI 11-12-2024
- CDXS 02-26-2025
- Dividend Yield
- OABI N/A
- CDXS N/A
- EPS Growth
- OABI N/A
- CDXS N/A
- EPS
- OABI N/A
- CDXS N/A
- Revenue
- OABI $20,409,000.00
- CDXS $64,446,000.00
- Revenue This Year
- OABI N/A
- CDXS N/A
- Revenue Next Year
- OABI $78.61
- CDXS $2.02
- P/E Ratio
- OABI N/A
- CDXS N/A
- Revenue Growth
- OABI N/A
- CDXS N/A
- 52 Week Low
- OABI $3.16
- CDXS $2.53
- 52 Week High
- OABI $6.55
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- OABI 32.70
- CDXS 58.39
- Support Level
- OABI $3.16
- CDXS $4.24
- Resistance Level
- OABI $3.29
- CDXS $5.51
- Average True Range (ATR)
- OABI 0.13
- CDXS 0.32
- MACD
- OABI -0.02
- CDXS 0.00
- Stochastic Oscillator
- OABI 9.09
- CDXS 82.68
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.